SMAD4 Methylation & Expression Levels in Non-melanocytic Skin Cancers;

Status Recruiting

Clinical Trial Summary

Non-melanocytic skin cancers are the most common type of cancer worldwide. In the development of this cancer type, environmental factors such as UV and smoking are emphasized. Epigenetics are genetic conditions that develop due to environmental factors and can be inherited. Epigenetic modifications such as DNA methylation play an integral role in carcinogenesis, cancer progression and metastasis. The TGF-/ SMAD4 pathway plays a tumor suppressive role in cancer pathogenesis. Epigenetic changes in this pathway also lead to a decrease in expression level, leading to different types of cancer. However, there is no study showing the epigenetic relationship between non-melanocytic skin cancer and SMAD4 methylation. In this study we planned, it was aimed to show the change in SMAD4 methylation and SMAD4 RNA expression level in cancerous tissue. In addition, it is planned to measure the SMAD4 protein positivity rate in non-melanocytic cancers as an immunohistochemical marker. In this context, 60 patients who applied to Trakya University Dermatology and Venereal Diseases Outpatient Clinic and diagnosed with non-melanocytic skin cancer clinically and dermoscopically will be included in the study. Tissue materials obtained from both cancerous and intact skin of the patients will be examined in Trakya University Medical Biophysics and Medicine Pathology laboratories through various steps. Our project is the first study to be conducted on this subject in terms of handling all non-melanocytic skin cancers, using human tissue and having a large sample. In addition, with the data to be obtained; We think that better clarification of the role of SMAD4 in non-melanocytic cancers and the use of SMAD4 as both a prognostic factor and an immunohistochemical marker in future studies will prevent this study. Again, we anticipate that different treatment modalities will be developed and different functional studies can be designed through this pathway.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04759261
Study type	Interventional
Source	Trakya University
Contact	Yildiz Gursel, MD
Phone	90 505 537 30 63
Email	yildizgrsl@gmail.com
Status	Recruiting
Phase	N/A
Start date	December 1, 2020
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Completed	`NCT04229277` - Fast Track Diagnosis of Skin Cancer by Advanced Imaging	N/A
Completed	`NCT05608902` - Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
Completed	`NCT05077033` - Intratumoral phIL12 GET	Phase 1
Active, not recruiting	`NCT04928222` - Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)	Phase 1/Phase 2
Recruiting	`NCT04929535` - Hydrogen Peroxide Trial to Investigate the Efficacy of 30%H2O2 as a Topical Application Before Definitive Treatment	Phase 2
Completed	`NCT02662244` - Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma	N/A
Completed	`NCT00959647` - A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study	Phase 2
Completed	`NCT00793169` - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed	`NCT00586040` - Photochemical Tissue Bonding	Phase 2
Completed	`NCT00473343` - Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma	Phase 3
Active, not recruiting	`NCT06024629` - cOCT Versus LC-OCT for Diagnosing Basal Cell Carcinoma: a Diagnostic Cohort Study
Not yet recruiting	`NCT05324202` - New Imaging Procedures and Therapeutic Approach in Basal Cell Carcinoma Management	N/A
Withdrawn	`NCT04099446` - A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
Completed	`NCT02902822` - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo	N/A
Completed	`NCT01260987` - Fractional CO2 Laser Assisted Photodynamic Therapy	Phase 2/Phase 3
Completed	`NCT01201915` - A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma	Phase 2
Completed	`NCT01208831` - An East Asian Study of LDE225	Phase 1
Completed	`NCT01014819` - A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions	N/A
Completed	`NCT00472043` - PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms